Cargando…
Marginal Zone B-Cells, a Gatekeeper of Innate Immunity
To maintain the integrity of an organism constantly challenged by pathogens, the immune system is endowed with a variety of cell types. B lymphocytes were initially thought to only play a role in the adaptive branch of immunity. However, a number of converging observations revealed that two B-cell s...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341996/ https://www.ncbi.nlm.nih.gov/pubmed/22566852 http://dx.doi.org/10.3389/fimmu.2011.00063 |
_version_ | 1782231609642057728 |
---|---|
author | Zouali, Moncef Richard, Yolande |
author_facet | Zouali, Moncef Richard, Yolande |
author_sort | Zouali, Moncef |
collection | PubMed |
description | To maintain the integrity of an organism constantly challenged by pathogens, the immune system is endowed with a variety of cell types. B lymphocytes were initially thought to only play a role in the adaptive branch of immunity. However, a number of converging observations revealed that two B-cell subsets, marginal zone (MZ) and B1 cells, exhibit unique developmental and functional characteristics, and can contribute to innate immune responses. In addition to their capacity to mount a local antibody response against type-2 T-cell-independent (TI-2) antigens, MZ B-cells can participate to T-cell-dependent (TD) immune responses through the capture and import of blood-borne antigens to follicular areas of the spleen. Here, we discuss the multiple roles of MZ B-cells in humans, non-human primates, and rodents. We also summarize studies – performed in transgenic mice expressing fully human antibodies on their B-cells and in macaques whose infection with Simian immunodeficiency virus (SIV) represents a suitable model for HIV-1 infection in humans – showing that infectious agents have developed strategies to subvert MZ B-cell functions. In these two experimental models, we observed that two microbial superantigens for B-cells (protein A from Staphylococcus aureus and protein L from Peptostreptococcus magnus) as well as inactivated AT-2 virions of HIV-1 and infectious SIV preferentially deplete innate-like B-cells – MZ B-cells and/or B1 B-cells – with different consequences on TI and TD antibody responses. These data revealed that viruses and bacteria have developed strategies to deplete innate-like B-cells during the acute phase of infection and to impair the antibody response. Unraveling the intimate mechanisms responsible for targeting MZ B-cells in humans will be important for understanding disease pathogenesis and for designing novel vaccine strategies. |
format | Online Article Text |
id | pubmed-3341996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Frontiers Research Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33419962012-05-07 Marginal Zone B-Cells, a Gatekeeper of Innate Immunity Zouali, Moncef Richard, Yolande Front Immunol Immunology To maintain the integrity of an organism constantly challenged by pathogens, the immune system is endowed with a variety of cell types. B lymphocytes were initially thought to only play a role in the adaptive branch of immunity. However, a number of converging observations revealed that two B-cell subsets, marginal zone (MZ) and B1 cells, exhibit unique developmental and functional characteristics, and can contribute to innate immune responses. In addition to their capacity to mount a local antibody response against type-2 T-cell-independent (TI-2) antigens, MZ B-cells can participate to T-cell-dependent (TD) immune responses through the capture and import of blood-borne antigens to follicular areas of the spleen. Here, we discuss the multiple roles of MZ B-cells in humans, non-human primates, and rodents. We also summarize studies – performed in transgenic mice expressing fully human antibodies on their B-cells and in macaques whose infection with Simian immunodeficiency virus (SIV) represents a suitable model for HIV-1 infection in humans – showing that infectious agents have developed strategies to subvert MZ B-cell functions. In these two experimental models, we observed that two microbial superantigens for B-cells (protein A from Staphylococcus aureus and protein L from Peptostreptococcus magnus) as well as inactivated AT-2 virions of HIV-1 and infectious SIV preferentially deplete innate-like B-cells – MZ B-cells and/or B1 B-cells – with different consequences on TI and TD antibody responses. These data revealed that viruses and bacteria have developed strategies to deplete innate-like B-cells during the acute phase of infection and to impair the antibody response. Unraveling the intimate mechanisms responsible for targeting MZ B-cells in humans will be important for understanding disease pathogenesis and for designing novel vaccine strategies. Frontiers Research Foundation 2011-12-13 /pmc/articles/PMC3341996/ /pubmed/22566852 http://dx.doi.org/10.3389/fimmu.2011.00063 Text en Copyright © 2011 Zouali and Richard. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited. |
spellingShingle | Immunology Zouali, Moncef Richard, Yolande Marginal Zone B-Cells, a Gatekeeper of Innate Immunity |
title | Marginal Zone B-Cells, a Gatekeeper of Innate Immunity |
title_full | Marginal Zone B-Cells, a Gatekeeper of Innate Immunity |
title_fullStr | Marginal Zone B-Cells, a Gatekeeper of Innate Immunity |
title_full_unstemmed | Marginal Zone B-Cells, a Gatekeeper of Innate Immunity |
title_short | Marginal Zone B-Cells, a Gatekeeper of Innate Immunity |
title_sort | marginal zone b-cells, a gatekeeper of innate immunity |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341996/ https://www.ncbi.nlm.nih.gov/pubmed/22566852 http://dx.doi.org/10.3389/fimmu.2011.00063 |
work_keys_str_mv | AT zoualimoncef marginalzonebcellsagatekeeperofinnateimmunity AT richardyolande marginalzonebcellsagatekeeperofinnateimmunity |